Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
Source: SeekingAlpha
2025-12-03 17:43:24 ET
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema December 3, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript
Pharvaris N.V.
NASDAQ: PHVS
PHVS Trading
1.73% G/L:
$26.72 Last:
64,092 Volume:
$26.08 Open:
PHVS Latest News
March 11, 2026 06:50:00 am
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
PHVS Stock Data
$1,492,567,159
37,790,994
N/A
37
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
